|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-1-29
|
|
pubmed:abstractText |
Fludarabine-based chemoimmunotherapy has well-recognised efficacy and short-term toxicity in the treatment of lymphoid malignancies. However, the presence and significance of prolonged cytopenias after completion of treatment have not been thoroughly quantified.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
331-4
|
|
pubmed:meshHeading |
pubmed-meshheading:19625344-Adult,
pubmed-meshheading:19625344-Aged,
pubmed-meshheading:19625344-Aged, 80 and over,
pubmed-meshheading:19625344-Anemia,
pubmed-meshheading:19625344-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19625344-Female,
pubmed-meshheading:19625344-Hematologic Diseases,
pubmed-meshheading:19625344-Humans,
pubmed-meshheading:19625344-Leukemia, Lymphoid,
pubmed-meshheading:19625344-Leukopenia,
pubmed-meshheading:19625344-Male,
pubmed-meshheading:19625344-Middle Aged,
pubmed-meshheading:19625344-Neoadjuvant Therapy,
pubmed-meshheading:19625344-Neutropenia,
pubmed-meshheading:19625344-Pancytopenia,
pubmed-meshheading:19625344-Prevalence,
pubmed-meshheading:19625344-Retrospective Studies,
pubmed-meshheading:19625344-Thrombocytopenia,
pubmed-meshheading:19625344-Time Factors,
pubmed-meshheading:19625344-Vidarabine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
|
|
pubmed:affiliation |
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
